Myxredlin, a Ready-to-Use IV Insulin, Approved
July 22, 2019 – The U.S. FDA has approved Myxredlin™ (insulin human in sodium chloride) injection, a new ready-to-use, short-acting insulin for intravenous (IV) infusion. The product, which is manufactured by Baxter Pharmaceuticals, is indicated to improve glycemic control in adults and pediatric patients who have diabetes mellitus.
Diabetes mellitus can be classified as either type 1 or type 2 diabetes. Type 1 diabetes is an autoimmune disease in which the body attacks the pancreas, compromising the organ’s ability to produce insulin. This form of diabetes often manifests in childhood, and is the most common form of diabetes diagnosed in children. It is also known as insulin-dependent diabetes, as some form of insulin is required to treat the condition. By contrast, type 2 diabetes is diagnosed more often in adults. It occurs when the body doesn’t make enough insulin, or isn’t able to properly use the insulin that it produces. While type 2 diabetes can be managed with diet, exercise, and non-insulin therapies in many cases, it often progresses to a point where insulin is required to manage blood sugar levels.
According to the manufacturer, Myxredlin may remove the need for a pharmacist to manually mix insulin for intravenous infusion to the correct dose. This removal of manual dosing could reduce the risk of medication errors. However, the Myxredlin is only intended for use under medical supervision in acute care settings, such as hospitals. Recommended dosing is based on the patient’s metabolic needs, blood glucose monitoring results, and glycemic control goal.
Myxredlin is available in a standard concentration of 100 units/100mL at a wholesale acquisition cost (WAC) of $420.00 for 12 single-dose containers.